Τόμος 16 (1998) – Τεύχος 3 – Άρθρο 4 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 16 (1998) – Issue 3 – Article 4 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Υβόννη Δημουλά, Μαρία Λυμπέρη, Πλούταρχος Κούρτης

Εργαστήριο Φυσιολογίας Σχολών Επιστημών Υγείας, Τεχνολογικό Εκπαιδευτικό Ίδρυμα Αθήνας και Εργαστήριο Πειραματικής Φυσιολογίας Ιατρικής Σχολής Πανεπιστημίου Αθηνών

Yvonne Dimoula, Maria Lymberi, Ploutarchos Kourtis

Laboratory of Physiology, Department of Health and Caring Professions, Technological Educational Institution of Athens and Laboratory of Physiology, Medical School, University of Athens

2. Pateron D., Augier J., Duclos-Vallee J.C., Jouanolle H., Hartman D.J., Beaugrand M.: High prevalence of abnormal thyroid tests in patients with chronic hepatitis C (CHC) before alpha interferon (IFN) therapy: relation with IFN induced thyroid dysfuntion. Hepatololy 14: 77A (1991)

3. Tran A., Quaranta J.F., Benzaken S., Thiers V., Chau H.T., Hastier P., Regnier D., Dreyfus G., Pradier C., Sadoul J.L., Hebuterne X., Pampal P.: High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 18: 253-257 (1993)

4. Marcellin P., Pouteau M., Baudin E., Colas-Linhart N., Degos F., Erlinger S., Bok B., Benhamou J.P.: Thyroid dysfunction induced by recombinant interferon in patients with chronic hepatitis C: a prospective study. Hepatology 14: 77A (1991)

5. Rumi M.G., Marcelli R., La Rosa L., Parravicini M.L., Covini G., Meroni P.L., Del Ninno E., Beck-Peccoz P.: High prevalence of thyroid dysfuntions in patients with HCV infection threated with interferon alpha 2 (IFN). Hepatology 16: 219A (1992)

6. Chung Y.H., Shong Y.K.: Development of thyroid autoimmunity after administration of recombinant human interferon-(2b for chronic viral hepatitis. Am. J. Gastroenterol. 88: 244-247 (1993)

7. Baudin E., Marcellin P., Pouteau M., Colas-Linhart N., Le Floch J.P., Lemmonier C., Benhamou J.P., Bock B: Reversibility or thyroid dysfuction induced by recombinant alpha interferon in chronic hepatitis C. Clin. Endocrinol. 39: 657-661 (1993)

8. Preziati D., La Rosa L., Covini G., Marcelli R., Rescalli S., Persani L., Del Ninno E., Meroni P.L., Colombo M., Beck-Peccoz P.: Autoimmunity and thyroid funtion in patients with chronic active hepatitis treated with recombinant interferon alpha-2. Eur. J. Endocrinol. 132: 587-593 (1995)

9. Imagawa A., Itoh N., Hanafusa T. Oda Y. Waguri M., Miyagawa J.I., Kono N., Kuwajima M., Matsuzawa Y.: Autoimmune ednocrine disease induced by recombinant interferon-( therapy for chronic active type C hepatitis. J. Clin. Endocrinol. Metabol. 80: 922-926 (1995)

10. Marazuela M., Garcia-Buey L., Gonzalez-Fernandez B., Garcia Monzon C., Arranz A., Borque M.J., Moreno-Otero R.: Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-( therapy. Clin. Endocrinol. 44: 635-642 (1996)

11. Fernandez-Soto L., Conzalez A., Escobar-Jimenez F., Vazquez R., Ocete E., Olea N., Salmeron J.: Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during and after discontinuing interferon therapy. Arch Intern. Med. 158: 1445-1448 (1998)

12. Pawlostsky J.M., Ben Yahia M., Andre C., Voisin M.C., Intrator L., Roudot-Thoraval F.: Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 19: 841-848 (1994)

13. Roti E., Gardini E., Minelli R., Bianconi L., Braverman L.E.: Prevalence of anti-thyroid peroxidase antibodies in serum in the elderly: comparison with other tests for anti-thyroid antibobies. Clin. Chem. 38: 88-92 (1992)

14. Bjoro T., Gaarder P.I., Smeland E.B., Kornstad L.: Thyroid antibodies in blood donors: prevalance and clinical significance. Acta Endocrinol 105: 324-329 (1984)

15. Tran A., Quaranta J.F., Benzaken S., Thiers V., Chau H.T., Hastier P., et al.: High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 18: 253-257 (1993)

16. Deutsch M., Doukakis S., Manesis E.K., Gioustozi A., Hess G., Horsch A., Hadziyannis S.: Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 26: 206-210 (1997)

17. Clifford B.D., Donahue D., Smith L. Gable E., Luttig B., Manns M., Bonkovsky H.L.: High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 21: 613-619 (1995)

18. Pateron D., Hartmann D.J., Duclos-Vallee J.C., Jouanolle H., Beaugrand M.: Latent autoimmune thyroid disease in patients with chroric HCV hepatitis. J. Hepatol.16: 244-245 (1992)

19. Tran A., Quaranta J.F., Beusnel C., Thiers V., De Souza M., Francois E., et al.: Hepatitis C virus and Hashimoto’s thyroiditis. Eur. J. Med. 1: 116-118 (1992)

20. Duclos-Vallee J.C., Johanet C., Duron F., Paterson D., Homberg J.C., Beaugrand M.: Prevalence elevee des anticorps anti-VHC chez les malades atteints de maladie de Hashimoto (abstract). Gastoenterol. Clin. Biol. 16: A224 (1992)

21. Quaranta J.R., Tran A., Regnier D., Lestestu R., Beusnel C., Fuzibet J.G. et. al.: High prevalence of antibodies to hepatitis C virus (HVC) in patients with anti-thyroid autoantibobies. J. Hepatol. 18: 136-138 (1993)

22. Del Prete GF, Tiri A., Mariotti S., Parronchi P., Pinchera A., Romagnani S, Ricci M.: Thyroiditis as a model of organ specific autoimmune disease. Clin. Exp. Rheumatol 7(Suppl. 3): 41-45 (1989)

23. Preziati D., La Rosa L., Covini G., et al.: Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur. J. Endocrinol. 132: 587-593 (1995)

24. Pangalis G.A., Griva E.: Recombinant alfa 2b interferon therapy in untreated, stages A and B chronic lympocytic leykemia. Cancer 61: 869-872 (1988)

25. Abdi E.A., Brien W., Verner P.M.: Autoimune thrombocytopenia related to interferon therapy. Scand. J. Haematol. 36: 515-519 (1986)

26. Ronnblom L.E., Oberg K.E., Alm G.V.: Possible induction of systemic lupus erythematosus by interferon treatment in a patient with manignant carcinoid tumor. Int. J. Med. 227: 207-210 (1990)

27. Fabris P., Betterle C., Floreani A., Greggio N.A., De Lazzari F., Naccarato R., et al.: Development of type I diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis (letter). Lancet 340: 558 (1992)

28. Ronnblom L.E., Alm G.V., Oberg K.E.: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 115: 178-183 (1991)

29. Corssmit E.P.M., Heyligenberg R., Endert E., Sauerwein H.P., Romijn J.A.: Acute effects of interferon-( administration on thyroid hormone metabolism in healthy men. J. Clin. Endocrinol. Metabol. 80: 3140-3144 (1995)

30. Berris B., Feiman V. Thyroid dysfuction and liver injury following alpha interferon treatment of chronic viral hepatitis. Dig. Dis. Sci. 36: 1657-11660 (1991)

31. Kodama T., Katabami S., Kamijo K., Katanuma A., Yamashita K., Azuma N., et al.: Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon. J. Gastroenterol. 29: 289-292 (1994)

32. Lisker- Melman M., Di Bisceglie A.M., Usala S.J., Weintraub B., Murray L.M., Hoofnagle J.H.: Development of thyroid disease during therapy for chronic viral hepatitis with interferon alpha. Gastroenterology 102: 2155-2160 (1992)

33. Fentiman I.S., Thomas B.S., Balkwill F.R., Rubens R.D., Hayward J.L.: Primary hypothyroidism associated with interferon therapy of breast cancer (letter). Lancet i: 1166 (1985)

34. Burman P., Totterman T.H., Oberg K., Karlsson F.A.: Thyroid autoimmunity in patients on long-term therapy with leykocyte-derived interferon. J. Clin. Endocrinol. Metab. 63: 1086-1090 (1986)

35. Ronnblom L.E., Alm G.V., Orberg K.E.: Autoimmunity after alpha interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 115: 178-183 (1991)

36. Schultz M., Muller R., von zur Muhlen A., Brabant G.: Induction of hyperthyroidism by interferon-alpha-2b (letter) Lancet i: 1452 (1989)

37. Eugene C., Tennenbaum R., Anciaux M.L., Quevauvilliers J., Bergue A.: Dysthyroidies auto-immunes induites par l’ interferon alpha lors du traitement d’ hepatites chroniques non-A, non-B. Gastroenterol. Clin. Biol. 17: 594-597 (1993)

38. Fentiman L.S., Thomas B.S. Balkwill F.R. Rubens R.D., Hayward J.L.: Primary hypothyroidism associated with interferon therapy of breast casncer (letter). Lancet i: 1166 (1985)

39. Burman P., Totterman T.H. Oberg, K., Karlsson F.A.: Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J. Clin. Endocrinol. Metab. 63: 1086-1090 (1986)

40. Ronnblom L.E., Alm G.V., Oberg, K.E.: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 115: 178-183 (1991)

41. Chem F.-Q., Okamura K., Sato K., Kuroda T., Mizokami T., Fujikawa M., Tsuji H., Okamura S., Fujishima M.: Reversible primary hypothyroidism with blocking or stimulating type TSH binging inhibitor immunoglobulin following recombinant interferon-( therapy in patients with pre-existing thyroid disorders. Clin. Endocrinol. 45: 207-214 (1996)

42. Marcellin P., Pouteau M., Renard P., Grynblat J.M., Colas Linhart N., Bardet P.: Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut 33: 855-856 (1992)

43. Radinovitch M., Manejias R.E., Rosso M., Abbey E.E.: Increased spreading of macrophages from mice treated with interferon inducers. Cell Immunol. 29: 86-95 (1997)

44. Jones T.H., Wadler S., Hupart K.H.: Endocrine-mediated mechanisms of fatigue during treatment with interferon-(. Semin. Oncol. 25(Suppl. 1): 54-63 (1998)

45. Herberman R.R., Ortaldo J.R., Bonnard G.D.: Augmentation by interferon of human natural and antibody-dependent cellmediated cytotoxicity. Nature 227: 221-3 (1979)

46. Baron S., Tyring S.K., Fleischmann W.R., Coppenhaver D.H., Niesel D.W., Klimpel G.R.: The interferons: mechanisms of actions and clinical applications. JAMA 226: 1375-1383 (1991)

47. Nagayama Y., Ohta K., Tsuruta M., Takeshita A., Kimura H., Hamasaki K., Ashizawa K., Nakata K., Yokoyama N., Nagataki S.: Exacerbation of thyroid autoimmunity by interferon ( treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocrin. J. 41: 565-572 (1994)

48. Marcellin P., Pouteau M., Benhamou J.-P.: Hepatitis C virus infection, alfa interferon therapy and thyroid dysfunction. J. Hepatol. 22: 364-369 (1995)

49. Durelli L., Bongioanni M.R., Ferrero B., Oggero A., Marzano A., Rizzetto M.: Interferon treatment f;or multiple sclerosis: Autoimmune complications may be lethal. Neurology 50: 570-571 (1998)

50. Durelli L., Ferrero B., Ecari U.: Betaferon safety trail group. The Betaferon safety trial: Autoimmunity during interferon beta-1b therapy for multiple sclerosis. J. Neurol. 245, 6/7:372 Abstarct No 146B (1998)

51. Ferrero B., Durelli L., Ecari U.: Betaferon safety trail group. The Betaferon safety trial. Prospective multicentric monitoring of autoimmunity during interfernon beta-1b therapy for multiple sclerosis. Neurology 50( Suppl. A33): Abstract No P01.071 (1998)

52. Bongioanni M.R., Durelli L., Ferrero B., Oggero A., Durazzo M., Rizzeto M., Manfredi E., Bergamasco B. (1996) Fuliminant autoimmune hepatitis and increased occurrence of serum autoantibodies during type ( interferon therapy for multiple sclerosis. J. Neurol. 243 (6 Suppl.): S53, Abstract No P278 (1996)

53. Tola M.R., Granieri E., Cavazzuti M., Merelli E., Motti L., Solime F., Malagu S., Rasi F.: Monitoring of autoimmune profile during treatment with beta-1b for multiple sclerosis. Multiple sclerosis 3,5: 343, Abstract No P228 (1997)

54. Trojano M., Avolio C., Linguori M., Zimatore G. B., De Robertis F., Paolicelli D., Giuliani F., Livera P.: rIFN Southern Italy group. Multicentric post-marketing effectiveness evaluation of rIFN™ treatment in a R.R. multiple sclerosi population from southern Italy. Multiple Sclerosis 4,4: 376, Abstract No P3008 (1998)

55. Durelli L., Bongioanni R., Ferrero B., Oggero A., Aimo G., Bergamasco B.: Autommune side effects during long-term interferon treatment of relapsing-remitting multiple sclerosis. Multiple Sclerosis 3,5: 276 Abstract No S048 (1997)

56. Ferrero B., Durelli L., Ecari U.: Betaferon safety trial group. Autoimmunity during interferon beta-1b therapy for multiple sclerosis. A multicentric nonitoring study. Multiple Sclerosis 4,4: 378, Abstract No P3014 (1998)

57. Schwid S.R., Goodman A.D., Mattson D.H.: Autoimmune hyperthyroidism in patients with multiple sclerosis treatment wirh interferon beta-1b. Arch. Neurol. 54: 1169-1170 (1997)

58. Burguera J.A., Casanova B., Cervello A., Coret F., Delolmo A.,Palao J., Taberner P., VillarroyaT.: Interferon beta-1b in the treatment of remittent-recurrent multiple sclerosis. The clinical experience of the Valencia group. Revista de Neurologia 25, 148: 1876-1879 (1997)

59. Oggero A., Bongioanni M., Marzano A., Aimo G., Gentile E., Rizzetto M., Durelli L.: Thyroid and liver autoimmunity during Interferon (IFN) treatment for Multiple Sclerosis (MS) may be at times lethal. Neurology 48, 3 Suppl. B: A245 P04.075 (1997)